EPHA1, EPH receptor A1, 2041

N. diseases: 119; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE The eph gene is overexpressed in several human carcinomas, suggesting that this gene may be involved in the neoplastic process of some tumors. 2825356 1987
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.060 AlteredExpression phenotype BEFREE EPH-A2, or ECK (a receptor for ephrin-A1), is ectopically expressed in most melanoma cell lines; the pathology where this expression is first manifested and the possible role of the receptor in tumor progression are unknown. 10502726 1999
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.030 GeneticVariation disease BEFREE HTK (hepatoma transmembrane kinase) is a receptor tyrosine kinase belonging to the EPH subfamily of tyrosine kinases. 10221518 1999
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms 		0.010 GeneticVariation group BEFREE HTK (hepatoma transmembrane kinase) is a receptor tyrosine kinase belonging to the EPH subfamily of tyrosine kinases. 10221518 1999
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE To screen for Eph proteins expressed in tumor blood vessels, we used tumor xenografts grown in nude mice from MDA-MB-435 human breast cancer cells or KS1767 human Kaposi's sarcoma cells. 11146556 2000
CUI: C0025202
Disease: melanoma
melanoma 		0.020 Biomarker disease BEFREE While a role for PTKs in human melanoma is less firmly established, human melanomas or melanoma cells have been reported to contain more tyrosine phosphate than normal melanocytes, and some receptor PTKs (EPH-A2/ ECK and EPH-B3) are overexpressed in over 90% of melanoma cell lines. 11095400 2000
CUI: C0036220
Disease: Kaposi Sarcoma
Kaposi Sarcoma 		0.020 AlteredExpression disease BEFREE To screen for Eph proteins expressed in tumor blood vessels, we used tumor xenografts grown in nude mice from MDA-MB-435 human breast cancer cells or KS1767 human Kaposi's sarcoma cells. 11146556 2000
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE These Eph receptors and ephrin ligands have also been identified as important regulators in the development and progression of cancer. 15147954 2004
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 Biomarker phenotype BEFREE More studies indicate that Eph receptors are involved in angiogenesis and tumorigenesis. 15029258 2004
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE These Eph receptors and ephrin ligands have also been identified as important regulators in the development and progression of cancer. 15147954 2004
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.060 AlteredExpression disease BEFREE Two factors, the ephrin type A receptor 1 and the prostaglandin E(2) receptor EP4 subtype, not previously considered in this context, were highlighted because of their particularly high (positive) correlation coefficients; immunostaining showed the products of these two genes to be localized in perinecrotic and necrotic regions and to be overexpressed in grade III GBMs, but not AAs. 14734472 2004
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.060 AlteredExpression disease BEFREE EphA8 was down-regulated in colon cancer, and EphA1/EphA8 was down-regulated in glioblastomas. 14726470 2004
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.050 AlteredExpression disease BEFREE Two factors, the ephrin type A receptor 1 and the prostaglandin E(2) receptor EP4 subtype, not previously considered in this context, were highlighted because of their particularly high (positive) correlation coefficients; immunostaining showed the products of these two genes to be localized in perinecrotic and necrotic regions and to be overexpressed in grade III GBMs, but not AAs. 14734472 2004
CUI: C0220767
Disease: Craniofrontonasal dysplasia
Craniofrontonasal dysplasia 		0.030 GeneticVariation disease BEFREE Recently, we have mapped a gene for CFNS in the pericentromeric region of the X chromosome that contains the EFNB1 gene, which encodes the ephrin-B1 ligand for Eph receptors. 15124102 2004
CUI: C0010278
Disease: Craniosynostosis
Craniosynostosis 		0.010 Biomarker disease BEFREE This is the only known mutation in the ephrin/Eph receptor signaling system in humans and provides clues to the biogenesis of craniosynostosis. 15166289 2004
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma 		0.010 AlteredExpression disease BEFREE Two factors, the ephrin type A receptor 1 and the prostaglandin E(2) receptor EP4 subtype, not previously considered in this context, were highlighted because of their particularly high (positive) correlation coefficients; immunostaining showed the products of these two genes to be localized in perinecrotic and necrotic regions and to be overexpressed in grade III GBMs, but not AAs. 14734472 2004
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 Biomarker phenotype BEFREE Mounting evidence suggests that Eph receptors, through de-regulated re-emergence of their mode of action in the embryo may direct cell movements and positioning during metastasis, invasion and tumour angiogenesis. 16012051 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Mounting evidence suggests that Eph receptors, through de-regulated re-emergence of their mode of action in the embryo may direct cell movements and positioning during metastasis, invasion and tumour angiogenesis. 16012051 2005
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 Biomarker phenotype BEFREE This review discusses these and other emerging roles of Eph receptors during oncogenesis. 16012051 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE EphA1 seems to be a marker of the differentiated normal epidermis and its downregulation in nonmelanoma skin cancer may contribute to carcinogenesis of these very frequent human tumors. 16862074 2006
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE These findings identify a novel Eph receptor signalling pathway with tumour-suppressor activity and predict that therapeutic intervention to activate EphB4 signalling will inhibit tumour progression. 16862147 2006
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 AlteredExpression phenotype BEFREE EphA1 seems to be a marker of the differentiated normal epidermis and its downregulation in nonmelanoma skin cancer may contribute to carcinogenesis of these very frequent human tumors. 16862074 2006
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.060 AlteredExpression phenotype BEFREE These findings identify a novel Eph receptor signalling pathway with tumour-suppressor activity and predict that therapeutic intervention to activate EphB4 signalling will inhibit tumour progression. 16862147 2006
CUI: C0037286
Disease: Skin Neoplasms
Skin Neoplasms 		0.020 AlteredExpression group LHGDN Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. 16862074 2006
CUI: C0007114
Disease: Malignant neoplasm of skin
Malignant neoplasm of skin 		0.010 AlteredExpression disease BEFREE We therefore investigated the expression of EphA1 in nonmelanoma skin cancers derived from the epidermis (56 basal cell carcinomas and 32 squamous cell carcinomas). 16862074 2006